Results 1 to 10 of about 57,963 (159)
Role of biofilm formation and antimicrobial resistance in urogenital Haemophilus influenzae isolates [PDF]
BMC MicrobiologyBackground Haemophilus influenzae (Hi) is increasingly detected in genital infections in humans and linked to septic abortion. We aimed to characterize 123 non-capsulated (non-typeable) Hi isolates from genital sites in women and investigate their ...
Nouria Belkacem +4 more
doaj +2 more sources
Multi-Antigen Protein Vaccine Confers Protection in a Murine Model Against Intranasal Haemophilus influenzae Challenge [PDF]
VaccinesBackground: Non-typeable Haemophilus influenzae (NTHi) is a major cause of acute respiratory tract infections and chronic airway disease, despite its clinical importance, no licensed vaccine is available, largely due to the extensive genetic and ...
Nouria Belkacem +2 more
doaj +2 more sources
Haemophilus influenzaeInfections [PDF]
New England Journal of Medicine, 1972 Of the six typeable strains of this organism, type b is the most virulent, accounting for 95% of serious infections in children. Unexpectedly, in adults, nearly two thirds of isolates from blood and CSF were found to be nontypeable. The spectrum of clinical disease associated with type b and nontypeable strains is discussed.
J D, Connor, W L, Nyhan
+9 more sources
Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules
BMC Infectious Diseases, 2021 Background Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in France in 1992 as a 3 + 1 scheme at 2, 3, and 4 months (primary vaccination) with a booster at the age of 16–18 months. The vaccination was simplified in 2013 to a 2 +
Eva Hong +6 more
doaj +1 more source
npj Vaccines, 2022 Since January 2018, mandatory vaccination against meningococci serogroup C has been implemented in France for children
Samy Taha +2 more
doaj +1 more source
The rapid rebound of invasive meningococcal disease in France at the end of 2022
Journal of Infection and Public Health, 2023 Background: Invasive meningococcal disease (IMD) cases declined upon the implementation of non-pharmaceutical measures to control the COVID-19 pandemic. A rebound in IMD cases was feared upon easing these measures.
Samy Taha +6 more
doaj +1 more source
Product review on the IMD serogroup B vaccine Bexsero®
Human Vaccines & Immunotherapeutics, 2022 Bexsero® is a multicomponent vaccine composed of four major proteins of Neisseria meningitidis: the fHbp, NHBA, NadA and PorA. This vaccine was licensed against invasive meningococcal disease (IMD) due to serogroup B isolates.
Ala-Eddine Deghmane, Muhamed-Kheir Taha
doaj +1 more source
Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease
BMC Research Notes, 2020 Objective Few data are available on the association between SARS-CoV-2 and secondary bacterial infections. Such an association was described for flu and invasive meningococcal disease (IMD).
Muhamed-Kheir Taha, Ala-Eddine Deghmane
doaj +1 more source
Infectious Diseases and Therapy, 2023 Introduction Invasive meningococcal disease (IMD) due to serogroup W meningococci (MenW) is consistently reported with atypical clinical manifestations, including gastrointestinal symptoms, bacteremic pneumonia, and septic arthritis.
Isabelle Bertrand-Gerentes +5 more
doaj +1 more source
Analysis of Haemophilus species in patients with respiratory tract infections in Yaoundé, Cameroon
International Journal of Infectious Diseases, 2020 Objectives: To identifyHaemophilus species and characterise the antimicrobial susceptibility of isolates from patients with respiratory tract infections (RTIs) in Cameroon.
Serges Tchatchouang +11 more
doaj +1 more source